Zdrowie i gospodarka · 14/06/2002
FDA Releases Draft Guidance on Assessing QT Interval Prolongation Risk in Pharmaceutical Studies
The FDA has made available a draft guidance document outlining principles for identifying the risk of QT interval prolongation in pharmaceuticals, aimed at protecting patients from life-threatening arrhythmias